Amorsa Therapeutics, a
neuropharmaceutical company specializing in treating nervous system disorders,
has entered a partnership with Janssen Pharmaceuticals Inc.
Through an option and license
agreement, Janssen will gain worldwide exclusivity for one of Amorsa’s preclinical drug
candidates. Amorsa will develop the product at the pre-clinical stage, while
Janssen will take on responsibility for subsequent clinical, regulatory and
commercial development. Amorsa will be paid upfront and receive funding for
research in the agreement, which is being facilitated by Johnson & Johnson
Innovation.
"Janssen is an ideal
partner for this program," Amorsa CEO Joe Blanchard said in a
statement. "We are thrilled to be working with Janssen to help us
address one of the most serious unmet medical needs of today –
treatment-resistant depression."
The drug will be based on
Amorsa’s proprietary ketamine analog technology; the company’s products aim to be
rapidly acting antidepressants with an extended duration of action.
Amorsa was founded in 2013 to
treat nervous system disorders -- including moderate-to-severe pain and
treatment-resistant depression -- by using breakthrough products and technology.
Its leadership team comes with a lengthy track record in developing novel
therapeutic treatments.
Alerts Sign-up